BROADER
HEALTH
BENEFITS

Viral suppression with oral ART was the first step, now it’s time to take your patients further

With 6 doses per year, following initiation,[1,2] 2-monthly VOCABRIA + REKAMBYS enables people living with HIV the opportunity to thrive through high adherence and treatment satisfaction vs regular daily oral therapy[3-8]

Improved treatment satisfaction vs regular daily oral therapy with VOCABRIA + REKAMBYS[3–4,8]

Treatment satisfaction scores improved significantly for people living with HIV receiving 2-monthly VOCABRIA + REKAMBYS vs regular daily oral therapy in clinical trials and in a real-world setting:

  • Greater improvement with VOCABRIA + REKAMBYS vs regular daily oral therapy BIC/FTC/TAF at Month 12 in SOLAR*[3]
  • Shown over the long-term vs regular daily oral therapy at Week 96 in CARES†[4]
  • Clinically important and significant improvement in treatment satisfaction when switching from regular daily oral therapy to VOCABRIA + REKAMBYS at Month 24 in CARLOS‡[7]
Improved treatment satisfaction vs daily oral therapy with VOCABRIA + REKAMBYS

The SOLAR primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to BIC/FTC/TAF at Month 12 (mITT-E: 1% [n=5/447] with plasma HIV-1 RNA ≥50 copies/mL vs 0.4% [n=1/223], respectively; adjusted difference = 0.7% [95% CI: -0.7%, 2.0%]; 4% non-inferiority margin).[3]
The CARES primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to daily oral therapy at Week 48 (ITT-E: 96% [n=246/255] with plasma HIV-1 RNA <50 copies/mL vs 97% [n=250/257], respectively; adjusted difference = -0.8% [95% CI: -3.7%, 2.3%]; -10% non-inferiority margin).[9]
CARLOS primary endpoint: 86% (n=301/351) of participants achieved HIV-1 RNA <50 copies/mL at Month 12 (defined as last available viral load at the injection 7 date ±12-week window).[10]

*Mean change in HIVTSQ score for those receiving 2-monthly VOCABRIA + REKAMBYS from baseline (57.9/66) to Month 12 vs daily oral therapy with BIC/FTC/TAF from baseline (58.4/66) to Month 12: +3.4 vs -1.6, respectively (p<0.001).[3]
†Mean change in HIVTSQ score for those receiving every-2-month VOCABRIA + REKAMBYS vs daily oral therapy, at Week 96: +27.1 vs 17.9, respectively (p<0.0001).[4]
‡Mean change in HIVTSQ score from baseline (55.0/66) to Month 24: +6.0 (p<0.001), which was greater than half of the baseline SD (10.0), therefore meeting the threshold for minimum clinically important difference.[8]

Discussing treatment options and goals beyond virologic suppression with your patients may be important 

Find out how shared decision making may improve care for your patients

Involvement in treatment decisions and satisfaction with care empowers people living with HIV to take charge of their own health, adhere to treatment and remain in care[11,12]

Explore how VOCABRIA + REKAMBYS may benefit people living with HIV, beyond viral suppression:

Patient preference

Read more

Adherence and retention in care

Read more

Clinical considerations

Read more

Contact us for support

Prescribing Information and Adverse Event Reporting for TIVICAY (dolutegravir) is available here.

ART=antiretroviral therapy; BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; CI=confidence interval; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; HIVTSQ=HIV-specific Treatment Satisfaction Questionnaire; ITT-E=intention-to-treat exposed; mITT-E=modified intention-to-treat exposed; RNA=ribonucleic acid.

References:

  1. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).
  2. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566–e577. doi: 10.1016/S2352-3018(23)00136-4.
  4. Kityo C, Mambule IK, Musaazi J. et al. Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nat Med. 2025. https://doi.org/10.1038/s41591-025-04041-7.
  5. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomized, multicentre, open-label, phase 3b, non-inferiority study. Published in Lancet. 2021; Vol. 396, Issue 10267, Pages 1994–2005. DOI: 10.1016/S0140-6736(20)32666-0.
  6. Muccini C, Capra N, Lolatto R, et al. Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SChoLART study. Presented at: The Italian Conference on AIDS and Antiviral Research (ICAR); May 21–23, 2025; Padua, Italy. Oral presentation 0C35.
  7. John M, Williams L, Nolan G, et al. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the injectable Antiretroviral therapy feasibility study (JABS). Published in HIV Medicine. 2024; Vol. 25, Issue 8, Pages 935–945. DOI: 10.1111/hiv.13647.
  8. Wyen C, Noe S, Jonsson-Oldenbüttel C, et al. 24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster TUPEB035.
  9. Kityo C, Mambule IK, Musaazi J, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;24(10):1083–1092. doi: 10.1016/S1473-3099(24)00289-5.
  10. Jonsson-Oldenbüttel C, Noe S, Wyen C, et al. 12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. Presented at: The 25th International AIDS Conference; July 22–26, 2024; Munich, Germany. Poster TUPEB095.
  11. Okoli C, Brough G, Allan B, et al. Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. AIDS Behav. 2021;25(5):1384–1395. doi: 10.1007/s10461-020-02973-4.
  12. Keelson SA, Addo JO, Amoah J. The impact of patient engagement on service quality and customer well-being: an introspective analysis from the healthcare providers’ perspective. Cogent Public Health. 2024;11(1):2340157. doi: 10.1080/27707571.2024.2340157.

REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.

PM-GB-CBR-WCNT-250010 | March 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.